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A B S T R A C T
Background
Tuberculosis is the primary cause of hospital admission in people living with HIV, and the likelihood of death in the hospital is unacceptably
high. The Alere Determine TB LAM Ag test (AlereLAM) is a point-of-care test and the only lateral flow lipoarabinomannan assay (LF-LAM)
assay currently commercially available and recommended by the World Health Organization (WHO). A 2019 Cochrane Review summarised
the diagnostic accuracy of LF-LAM for tuberculosis in people living with HIV. This systematic review assesses the impact of the use of LF-
LAM (AlereLAM) on mortality and other patient-important outcomes.
Objectives
To assess the impact of the use of LF-LAM (AlereLAM) on mortality in adults living with HIV in inpatient and outpatient settings.
To assess the impact of the use of LF-LAM (AlereLAM) on other patient-important outcomes in adults living with HIV, including time to
diagnosis of tuberculosis, and time to initiation of tuberculosis treatment.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL);
MEDLINE (PubMed); Embase (Ovid); Science Citation Index Expanded (Web of Science), BIOSIS Previews, Scopus, LILACS; ProQuest
Dissertations and Theses; ClinicalTrials.gov; and the WHO ICTRP up to 12 March 2021.
Selection criteria
Randomized controlled trials that compared a diagnostic intervention including LF-LAM with diagnostic strategies that used smear
microscopy, mycobacterial culture, a nucleic acid amplification test such as  Xpert MTB/RIF, or a combination of these tests. We
included adults (≥ 15 years) living with HIV.
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Data collection and analysis
Two review authors independently assessed trials for eligibility, extracted data, and analysed risk of bias using the Cochrane tool for
assessing risk of bias in randomized studies. We contacted study authors for clarification as needed. We used risk ratio (RR) with 95%
confidence intervals (CI). We used a fixed-eQect model except in the presence of clinical or statistical heterogeneity, in which case we used
a random-eQects model. We assessed the certainty of the evidence using GRADE.
Main results
We included three trials, two  in inpatient settings and one in outpatient settings. All trials were conducted in sub-Saharan Africa and
assessed the impact of diagnostic strategies that included LF-LAM on mortality when the test was used in conjunction with other
tuberculosis diagnostic tests or clinical assessment for clinical decision-making in adults living with HIV.
Inpatient settings
In inpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy likely reduces mortality in people living with HIV
at eight weeks compared to routine tuberculosis diagnostic testing without LF-LAM (pooled RR 0.85, 95% CI 0.76 to 0.94; 5102 participants,
2 trials; moderate-certainty evidence). That is, people living with HIV who received LF-LAM had 15% lower risk of mortality. The absolute
eQect was 34 fewer deaths per 1000 (from 14 fewer to 55 fewer).
In inpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy probably results in a slight increase in the
proportion of people living with HIV who were started on tuberculosis treatment compared to routine tuberculosis diagnostic testing
without LF-LAM (pooled RR 1.26, 95% CI 0.94 to 1.69; 5102 participants, 2 trials; moderate-certainty evidence).
Outpatient settings
In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may reduce mortality in people living with
HIV at six months compared to routine tuberculosis diagnostic testing without LF-LAM (RR 0.89, 95% CI 0.71 to 1.11; 2972 participants, 1
trial; low-certainty evidence). Although this trial did not detect a diQerence in mortality, the direction of eQect was towards a mortality
reduction, and the eQect size was similar to that in inpatient settings.
In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may result in a large increase in the proportion
of people living with HIV who were started on tuberculosis treatment compared to routine tuberculosis diagnostic testing without LF-LAM
(RR 5.44, 95% CI 4.70 to 6.29, 3022 participants, 1 trial; low-certainty evidence).
Other patient-important outcomes
Assessment of other patient-important and implementation outcomes in the trials varied. The included trials demonstrated that a higher
proportion of people living with HIV were able to produce urine compared to sputum for tuberculosis diagnostic testing; a higher proportion
of people living with HIV were diagnosed with tuberculosis in the group that received LF-LAM; and the incremental diagnostic yield was
higher for LF-LAM than for urine or sputum Xpert MTB/RIF.
Authors' conclusions
In inpatient settings, the use of LF-LAM as part of a tuberculosis diagnostic testing strategy likely reduces mortality and probably results in
a slight increase in tuberculosis treatment initiation in people living with HIV. The reduction in mortality may be due to earlier diagnosis,
which facilitates prompt treatment initiation. In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy
may reduce mortality and may result in a large increase in tuberculosis treatment initiation in people living with HIV. Our results support
the implementation of LF-LAM to be used in conjunction with other WHO-recommended tuberculosis diagnostic tests to assist in the rapid
diagnosis of tuberculosis in people living with HIV.
P L A I N   L A N G U A G E   S U M M A R Y
Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan test in people living with HIV
What was the aim of this review?
Tuberculosis is the leading cause of death in people living with HIV. The disease is particularly diQicult to diagnose in people living with
HIV, in part because it is oRen challenging to produce sputum for diagnosis. The lateral flow urine lipoarabinomannan test (LF-LAM) is a
World Health Organization (WHO)-recommended rapid test to assist in the detection of active tuberculosis in people living with HIV. This
review is limited to studies that used the Alere Determine TB LAM Ag test (AlereLAM), which is the only LF-LAM test currently recommended
by the WHO; thus LF-LAM refers only to AlereLAM in this review. Rapid and early tuberculosis diagnosis may allow for prompt treatment
and prevent severe illness and death. The aim of this review was to determine whether the use of LF-LAM testing had an eQect on death
and other patient-important outcomes in people living with HIV.
Key messages
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In inpatient settings, the use of LF-LAM as part of a tuberculosis diagnostic testing strategy likely reduces deaths and probably results in a
slight increase in tuberculosis treatment initiation in people living with HIV.
In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may reduce deaths and may result in a large
increase in tuberculosis treatment initiation in people living with HIV.
What was studied in the review?
We searched for trials in adults (15 years and older) that evaluated the eQect of a tuberculosis diagnostic strategy that included the LF-LAM
test compared to standard care using other WHO-recommended diagnostic tests in adults living with HIV.
What were the main results of the review?
We identified three trials, two in inpatient settings and one in outpatient settings.
Inpatient settings
In inpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy likely reduces mortality in people living with
HIV at eight weeks compared to routine tuberculosis diagnostic testing without LF-LAM (2 trials, 5102 participants, moderate-certainty
evidence).
In inpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy probably results in a slight increase in the
proportion of people living with HIV who were started on tuberculosis treatment compared to routine tuberculosis diagnostic testing
without LF-LAM (2 trials, 5102 participants moderate-certainty evidence).
Outpatient settings
In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may reduce mortality in people living with HIV
at six months compared to routine tuberculosis diagnostic testing without LF-LAM (1 trial, 2972 participants, low-certainty evidence).
In outpatient settings, the use of LF-LAM testing as part of a tuberculosis diagnostic strategy may result in a large increase in the proportion
of people living with HIV who were started on tuberculosis treatment compared to routine tuberculosis diagnostic testing without LF-LAM
(1 trial, 3022 participants, low-certainty evidence).
Other patient-important outcomes
The included studies assessed other patient-important outcomes in diQerent ways. The studies demonstrated that more people living with
HIV were able to produce urine compared to sputum for tuberculosis diagnostic testing, and more people living with HIV were diagnosed
with tuberculosis in the group that received LF-LAM.
How up-to-date is the review?
We searched for relevant trials up to 12 March 2021.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   E<ect of LF-LAM compared to no LF-LAM on mortality and tuberculosis treatment initiation in people living with HIV,
inpatient settings
Patient or population: adults living with HIV
Setting: inpatients (Peter 2016 in 10 hospitals in South Africa, Tanzania, Zambia and Zimbabwe; Gupta-Wright 2018 in 2 hospitals in South Africa and Malawi)
Intervention: diagnostic strategy including LF-LAM





























In inpatient settings, the use of LF-LAM testing as part of
a tuberculosis diagnostic strategy likely reduces mortal-
ity in people living with HIV at eight weeks compared to




305 per 1000 384 per 1000
(287 to 515)






In inpatient settings, the use of LF-LAM testing as part
of a tuberculosis diagnostic strategy probably results in
a slight increase in the proportion of people living with
HIV who were started on tuberculosis treatment com-
pared to routine tuberculosis diagnostic testing without
LF-LAM.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: confidence interval; LF-LAM: lateral flow urine lipoarabinomannan assay; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.



































































































































































































aWe did not downgrade. In  Gupta-Wright 2018, investigators, all study staQ (other than the laboratory technician and statistician), hospital-attending clinical teams, and
participants were masked to the study group allocation. In Peter 2016, neither participants nor research nurses were masked to either allocation or test results. However, we
doubt that the test results were biased in light of this.
bWe downgraded one level for indirectness. The two trials were conducted in African countries. We do not have direct evidence of the applicability of the findings to other settings
outside of Africa, although we note that Peter 2016 took place at 10 sites across four countries, and Gupta-Wright 2018 took place in two sites across two countries. In Gupta-
Wright 2018, the test was conducted in the laboratory, not at the point of care. In addition, the intervention in Gupta-Wright 2018 was a combination of urine LAM and urine Xpert.




Summary of findings 2.   E<ect of LF-LAM compared to no LF-LAM on mortality and tuberculosis treatment initiation in people living with HIV,
outpatient settings
Patient or population: adults living with HIV
Settings: outpatients (Grant 2020  in 24 primary healthcare clinics in South Africa)
Intervention: diagnostic strategy including LF-LAM



















102 per 1000 90 per 1000
(72 to 113)






In outpatient settings, the use of LF-LAM testing as part
of a tuberculosis diagnostic strategy may reduce mor-
tality in people living with HIV at six months compared





114 per 1000 618 per 1000
(534 to 714)






In outpatient settings, the use of LF-LAM testing as part
of a tuberculosis diagnostic strategy may result in a
large increase in the proportion of people living with HIV
who were started on tuberculosis treatment compared
to routine tuberculosis diagnostic testing without LF-
LAM.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; LF-LAM: lateral flow urine lipoarabinomannan assay; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence



































































































































































































Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded one level for indirectness. Only one trial was included, which was conducted in South Africa. We do not have direct evidence of the applicability of the findings
to other settings.
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B A C K G R O U N D
The same or similar text appears in the Background  section  in
several other Cochrane protocols and reviews on tests for
diagnosing tuberculosis (Bjerrum 2019; Kay 2020; Kohli 2021;
Shapiro 2021).
Description of the condition
Tuberculosis (TB) is an airborne infection caused by the bacterium
Mycobacterium tuberculosis. Although pulmonary tuberculosis
(infection in the lungs) is the most common form of the
disease, tuberculosis can aQect almost any other site in the body
(extrapulmonary tuberculosis). Globally in 2019, 10 million people
were estimated to become sick due to tuberculosis, of whom 1.4
million died (including 208,000 people living with HIV), making
tuberculosis a leading cause of death due to an infectious disease
in adults (WHO Global Tuberculosis Report 2020). Tuberculosis
is the primary cause of hospital admission and death in people
living with HIV, with cohort studies demonstrating an in-hospital
attributable mortality of 25% in HIV-positive adults and 30% in HIV-
positive children across regions (Ford 2016). A systematic review of
health facility-based autopsy studies demonstrated that in-hospital
mortality may be even higher, with tuberculosis accounting for
approximately 40% of deaths in HIV-positive people (Gupta 2015).
Furthermore, it is likely that current estimates of mortality that rely
on verbal autopsies underestimate mortality due to HIV-associated
tuberculosis (Karat 2017). Importantly, in almost half of those
with tuberculosis, the disease remained undiagnosed at the time
of death (Gupta 2015). Tuberculosis is a curable infection, and
global policy emphasizes the importance of early diagnosis and
initiation of eQective treatment to improve individual outcomes
and decrease transmission (Barrera 2015; WHO Global Tuberculosis
Report 2020). The World Health Organization (WHO) estimates
that, from 2000 to 2019, more than 60 million lives were saved
by diagnosing and treating tuberculosis. The COVID-19 pandemic
threatens to reverse the gains made in recent years. A modelling
study by the WHO suggests that there could be between 200,000
and 400,000 additional tuberculosis deaths in 2020 if, over a period
of three months, 25% to 50% fewer people were detected and
treated with tuberculosis (WHO Global Tuberculosis Report 2020).
In 2019, there was a substantial gap (2.9 million) between the 10
million estimated cases of tuberculosis and the number of people
newly diagnosed and reported to national programmes (WHO
Global Tuberculosis Report 2020). Even those who are diagnosed
oRen face extensive delays (Hanson 2017; Sreeramareddy
2014). The agreed-upon best reference standard for pulmonary
tuberculosis is sputum culture (Lewinsohn 2017). However, culture
is a relatively complex and slow procedure, and test results may
not be available for two to eight weeks. Xpert MTB/RIF (Cepheid,
Sunnyvale, USA), Xpert Ultra (Cepheid, Sunnyvale, USA), and
Truenat (Molbio Diagnostics/Bigtec Labs, Goa/Bengaluru, India) are
molecular diagnostic assays that use nucleic acid amplification
to determine the presence of M tuberculosis and resistance to
rifampicin (one of the core first-line antibiotics used to treat
tuberculosis). They are recommended by the WHO as initial tests
for any person being evaluated for tuberculosis (WHO Consolidated
Guidelines (Module 3) 2020). Xpert MTB/RIF and Xpert Ultra
can be used to test extrapulmonary specimens; however, for
most non-respiratory specimens, the sensitivity is lower than
for sputum specimens (Kohli 2021). Individuals with tuberculosis
and HIV co-infection face particular challenges since they are
oRen unable to produce sputum specimens and are more likely
than HIV-negative individuals to have extrapulmonary disease,
which is harder to diagnose (Pai 2016; Shivakoti 2017). The
WHO recommends that people living with HIV be systematically
screened for active tuberculosis at each visit to a health facility
(WHO Compendium of WHO Guidelines 2018). Typically, screening
consists of evaluation for four symptoms of tuberculosis: cough,
fever, night sweats, and weight loss, followed, for those who
screen positive, by microbiological testing, which should include
a WHO-recommended rapid diagnostic test in all individuals
being evaluated for tuberculosis (WHO Consolidated Guidelines
(Module 3) 2020). However, increasing data from prevalence
surveys demonstrate high rates of tuberculosis in asymptomatic
individuals (WHO Global Tuberculosis Report 2020), highlighting
the gap in current symptom-based screening approaches, which
is particularly pertinent for those at higher risk of disease
progression, such as people living with HIV.
There is an urgent need for a rapid non-sputum-based diagnostic
test for tuberculosis (WHO Target Product Profile 2014). Such a
biomarker-based diagnostic test should ideally be highly sensitive,
enable a short time to diagnosis (less than one hour), have
minimal maintenance and ideally no calibration, and be low
cost (< USD 6) (WHO Target Product Profile 2014). There has
been growing interest in the detection of mycobacterial antigens
such as lipoarabinomannan (LAM) in urine, a specimen that is
easy to collect and process without the infection control risks
associated with the collection of sputum. Despite increasing
interest in the development of biomarker-based tuberculosis
diagnostics (MacLean 2019), only one biomarker-based test has
been recommended by the WHO for tuberculosis diagnosis: the
lateral flow lipoarabinomannan assay (LF-LAM) (WHO Consolidated
Guidelines (Module 3) 2020).
Description of the intervention
The LF-LAM assay is a commercially available point-of-care test
for active tuberculosis. This review is limited to studies that used
the Alere Determine TB LAM Ag (AlereLAM) (Abbott, Palatine, IL,
USA, previously Alere Inc, Waltham, MA, USA), which is the only LF-
LAM test currently recommended by the WHO; thus in the context
of this review, LF-LAM refers only  to AlereLAM.  LF-LAM is an
immunocapture assay that detects LAM antigen in urine. LAM is
a lipopolysaccharide present in mycobacterial cell walls (Brennan
2003), which is released from metabolically active or degenerating
bacterial cells during tuberculosis disease (Briken 2004). LAM is
detectable in the urine of people with active tuberculosis disease
by enzyme-linked immunosorbent assay (ELISA) and the lateral
flow testing platforms (Lawn 2012; Minion 2011; Shah 2016). LF-
LAM is performed manually by applying 60 µL of urine to the
test strip and incubating at room temperature for 25 minutes
(Alere 2020). The strip is then inspected by eye. The intensity of
any visible band on the test strip is graded by comparing it with
the intensities of the bands on a manufacturer-supplied reference
scale card. Of note, the reference scale was revised in January
2014. Prior to January 2014, the reference scale card included five
bands (grade 1 representing a very low intensity band to grade
5 representing a high/dark intensity band).  ARer January 2014,
the manufacturer revised the reference scale card to have four
reference bands, such that the band intensity for the new grade 1
corresponded to the band intensity for the previous grade 2). Under
the current manufacturer recommendations (using the revised four
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bands reference card), only bands that are grade 1 or higher are
considered positive (Alere 2020; Bjerrum 2019). If there are no
bands, or the bands present do not meet the degree of colour
intensity of the reference card (a faint band in the patient window
that is lighter than the first positive band on the reference card), the
test should be considered negative (WHO Operational Handbook
(Module 3) 2020).
The original Cochrane Review on the diagnostic accuracy of LF-
LAM,  Shah 2016, and a meta-analysis of an earlier generation of
the LAM ELISA test,  Minion 2011, both demonstrated increased
sensitivity for tuberculosis amongst people living with HIV with
advanced immunosuppression, compared to people living with
HIV with higher CD4 counts. Several hypotheses may explain
the higher sensitivity of urine LAM in people living with HIV
including higher bacillary burden and antigen load (Shah 2010),
greater likelihood of genitourinary tract tuberculosis, and greater
glomerular permeability to allow increased antigen levels in urine
(Lawn 2016; Minion 2011).
A Cochrane Review update on the diagnostic accuracy of LF-
LAM for the detection of tuberculosis in HIV-positive adults found
that LF-LAM  has a sensitivity  of 42% and specificity of 91% to
diagnose tuberculosis in HIV-positive individuals with tuberculosis
symptoms and sensitivity of 35% and specificity of 95% in HIV-
positive individuals not assessed for tuberculosis symptoms. LF-
LAM sensitivity is higher in inpatients compared to outpatients
and those with lower CD4 cell counts compared to those with
higher CD4 counts, whereas specificity is  lower  in both of these
subgroups (Bjerrum 2019).
In 2015, informed by the original Cochrane Review (Shah 2016),
the WHO made a conditional recommendation for using LF-LAM to
assist with the diagnosis of tuberculosis in HIV-positive people with
advanced disease, and a strong recommendation against using the
test “as a screening test for tuberculosis” based on the data among
unselected participants (WHO Consolidated Guidelines (Module 3)
2020). Based on evidence from randomized trials and an updated
Cochrane Review (Bjerrum 2019), the WHO currently recommends
that LF-LAM should be used to assist in the diagnosis of active
tuberculosis in HIV-positive adults, adolescents, and children (WHO
Consolidated Guidelines (Module 3) 2020). The key change from
the WHO 2015 guidelines is a broadening of the indication for use
of the LF-LAM assay among HIV-positive inpatients with signs and
symptoms of active tuberculosis (pulmonary and extrapulmonary)
irrespective of their CD4 count or inpatients with advanced HIV
or who are seriously ill or irrespective of signs and symptoms
of active tuberculosis if they have a CD4 count of less than 200
cells/µL. The updated guidelines recommend the use of LF-LAM
in HIV-positive outpatients and children with signs and symptoms
of tuberculosis (pulmonary or extrapulmonary tuberculosis, or
both forms) or irrespective of signs and symptoms of active
tuberculosis if they have a CD4 count of less than 100 cells/
µL, based on the generalization of data from adult inpatients,
whilst acknowledging the limitation  of the available data. The
WHO recommends that LF-LAM should not be used for general
tuberculosis screening in people without HIV “owing to sub-optimal
sensitivity”. The guidelines further suggest that LF-LAM should be
used in combination with existing tests, and not as a replacement
test (to existing tests) (WHO Consolidated Guidelines (Module 3)
2020).
Fujifilm SILVAMP TB LAM (FuijiLAM, co-developed by Foundation
for Innovative New Diagnostics (FIND), Geneva, Switzerland and
Fujifilm, Tokyo, Japan) is a new, urine-based, point-of-care test for
tuberculosis diagnosis in people living with HIV. In an individual
participant data meta-analysis that included five cohorts of people
living with HIV, FujiLAM was found to have superior sensitivity,
70.7% (95% confidence interval (CI) 59.0% to 80.8%), compared
to LF-LAM sensitivity of 42.3% (95% CI 31.7% to 51.8%), against a
microbiological reference standard; FujiLAM had lower specificity,
90.9% (95% CI 87.2% to 93.7%), compared to LF-LAM specificity of
95.3% (95% CI 92.2% to 97.7%) (Broger 2020). A post hoc analysis
of two cohort studies in which retrospective urine testing using
FujiLAM was undertaken demonstrated that FujiLAM would have
rapidly detected tuberculosis in up to 89% of patients who died
within three months, and that a negative FujiLAM result in patients
with tuberculosis was associated with between 86% and 97%
probability of survival to three months (Sossen 2020). A cohort
study from Ghana demonstrated that FujiLAM test positivity was
associated with an increased cumulative risk of mortality at six
months with a hazard ratio of 4.80 (95% CI 3.01 to 7.64) (Bjerrum
2020). At the time of this writing, additional prospective clinical
trials of FuijiLAM are ongoing to generate data for an updated WHO
policy review. We are not aware of any published trials that have
evaluated the eQect of FujiLAM on patient outcomes.
How the intervention might work
LF-LAM has lower sensitivity to detect tuberculosis in adults living
with HIV than the internationally suggested minimum target of
65% for non-sputum based tuberculosis tests, recommended for
trained microscopy technicians (WHO Target Product Profile 2014).
However, since it is a rapid point-of-care assay, it is expected that
obtaining a positive LF-LAM result will enable the prompt initiation
of tuberculosis therapy in people living with HIV who are more
likely to have advanced tuberculosis disease and be at higher risk
for adverse outcomes, including death. Additionally, since people
living with HIV are less likely to be able to produce sputum, which
is needed to perform other WHO-recommended rapid tests such
as Xpert MTB/RIF, Xpert Ultra, and Truenat, the use of LF-LAM may
increase the yield of microbiologically confirmed tuberculosis.
Why it is important to do this review
This review is important for several reasons. To our knowledge,
evidence of the eQects of diagnostic tests for tuberculosis on
patient outcomes has oRen been inferred from diagnostic accuracy
studies rather than randomized trials. An exception is the Xpert
MTB/RIF assay, described below. The impact of a diagnostic test
relies on the test results being used to guide clinical management
(di RuQano 2012). The best way to evaluate the eQect of a
test strategy is by using a test-and-treat randomized controlled
trial design. In this design, researchers assign patients to an
experimental versus a standard testing approach and measure the
(test strategy) eQect on mortality and other patient outcomes (di
RuQano 2012; Schünemann 2016).
Regarding the LF-LAM assay, a multisite randomized controlled
trial published in 2016 demonstrated that bedside urine LAM-
guided initiation of antituberculosis treatment in HIV-positive
adult inpatients with presumptive tuberculosis was associated
with decreased eight-week mortality (Peter 2016).  A second
large multisite randomized controlled trial has subsequently
been published (Gupta-Wright 2018), which did not demonstrate
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a significant decrease in mortality across the overall study
population, but found a reduction in mortality in three predefined
subgroups (participants with signs and symptoms of tuberculosis,
participants with CD4 < 100 cells/µL, and participants with
anaemia defined as haemoglobin < 8 g/dL).  In addition, several
observational cohort studies have suggested an association
between urine LAM positivity and higher disease severity and
mortality (Drain 2015; Drain 2017; LaCourse 2018; Lawn 2012; Lawn
2016). Despite the availability of WHO guidelines recommending
the use of urine LF-LAM testing for tuberculosis diagnosis
amongst  people living with HIV (WHO Consolidated Guidelines
(Module 3) 2020), urine LF-LAM testing has not been scaled up in
high tuberculosis/HIV burden countries (Saran 2019). A systematic
review will enable us to include a larger number of participants in
the analysis and investigate factors that aQect patient outcomes
across study settings.
Trials that assess the eQect of novel diagnostic tests on patient
outcomes are challenging because of the many and varied steps in
the test-treatment pathway (di RuQano 2012; Schünemann 2016).
Regarding Xpert MTB/RIF, we are aware of seven randomized trials
(Calligaro 2015; Churchyard 2015; Cox 2014; Mupfumi 2014; Ngwira
2019; Theron 2014a; Trajman 2015), and an individual participant
data meta-analysis that included five of these trials (Di Tanna
2019), which have examined the impact of the test on mortality
in relation to smear microscopy or diagnostic algorithms reflective
of usual practice. All seven aforementioned trials were conducted
in routine healthcare settings. However, only two of these trials
showed a statistically significant impact on mortality (Ngwira 2019;
Trajman 2015). Several reasons have been proposed to explain the
variable evidence for the impact of Xpert MTB/RIF on mortality,
including high rates of empirical treatment, insuQicient sample
size, and health system weaknesses (Auld 2016; Schumacher
2016; Schumacher 2019; Theron 2014b). A recently published
Cochrane Review highlights the challenges of determining the
eQect on all-cause mortality of using Xpert MTB/RIF rather than
smear microscopy and found that Xpert MTB/RIF probably reduced
mortality among people living with HIV and demonstrated a
variable eQect on other patient-important outcomes (Haraka 2021).
The aim of our systematic review is to determine the impact
of the use of LF-LAM on mortality and other patient-important
outcomes. This review, along with the Cochrane Review update on
the diagnostic test accuracy of LF-LAM (Bjerrum 2019), will have
important implications for the further scale-up of this diagnostic
test and the use of other similar tests in high tuberculosis burden
countries in the future. In addition, this review may contribute to
implications for future research concerning the design of trials of
new diagnostic tools.
O B J E C T I V E S
To assess the impact of the use of LF-LAM (AlereLAM) on mortality
in adults living with HIV in inpatient and outpatient settings.
To assess the impact of the use of LF-LAM (AlereLAM) on other
patient-important outcomes in adults living with HIV, including
time to diagnosis of tuberculosis, and time to initiation of
tuberculosis treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomized controlled trials (RCTs) and cluster-
RCTs. We excluded other study designs and data reported only in
abstracts, reviews, comments, and editorial notes.
Types of participants
We included participants who were adults (15 years and older is
considered 'adult' for purpose of tuberculosis surveillance) living
with HIV.
We included studies in which there was a suspicion of tuberculosis
amongst study participants based on the presence of signs and
symptoms compatible with tuberculosis (studies with symptomatic
participants), as well as studies that included participants who
presented for medical care irrespective of signs and symptoms
of tuberculosis (studies with unselected participants). Signs and




Diagnostic strategies that used LF-LAM either alone or in
combination with other tests.
Control
Diagnostic strategies that used smear microscopy, mycobacterial
culture, or Xpert MTB/RIF, or a combination of these tests, which did
not include LF-LAM.
Types of outcome measures
Primary outcomes
• All-cause mortality during study follow-up time.
• Tuberculosis-related mortality during study follow-up time.
Secondary outcomes
• Time to diagnosis of tuberculosis.
• Time to tuberculosis treatment initiation.
• Time from diagnosis to tuberculosis treatment initiation.
• Proportion of study participants who were diagnosed with
tuberculosis.
• Proportion of study participants who were treated
for tuberculosis.
• Proportion of study participants who were treated for
tuberculosis but did not have tuberculosis.
• Proportion of study participants who were able to produce a
specimen for diagnostic testing.
• Incremental diagnostic yield due to addition of LF-LAM to the
diagnostic algorithm.
• Tuberculosis-related treatment outcomes (treatment success or
failure, relapse or cure).
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Search methods for identification of studies
Electronic searches
The search for this review was conducted in conjunction with the
search for a Cochrane Review update on the diagnostic accuracy
of AlereLAM (Bjerrum 2019). That literature search was conducted
up to 11 May 2018. In addition, specifically for this intervention
review, we conducted a search up to 12 March 2021 in the following
databases, using the search terms reported in Appendix 1:
• Cochrane Infectious Diseases Group Specialized Register;
• Cochrane Central Register of Controlled Trials (CENTRAL) (2021,
Issue 3);
• MEDLINE (PubMed, from 1966 to 12 March 2021);
• Embase (Ovid, from 1947 to 12 March 2021);
• Science Citation Index Expanded (SCI-EXPANDED, from 1900 to
12 March 2021), Conference Proceedings Citation Index - Science
(CPCI-S, from 1900 to 12 March 2021), and BIOSIS Previews (from
1926 to 12 March 2021), all three using the Web of Science
platform;
• LILACS (Latin American and Caribbean Health Science
Information database) (BIREME, from 1982 to 12 March 2021);
• Scopus (from 1995 to 12 March 2021).
We also searched US National Institutes of Health Ongoing Trials
Register ClinicalTrials.gov (www.clinicaltrials.gov/) and the World
Health Organization International Clinical Trials Registry Platform
(WHO ICTRP, apps.who.int/trialsearch/) to identify ongoing trials,
and ProQuest Dissertations & Theses A&l (from 1861) to identify
relevant dissertations (searches conducted up to 12 March 2021).
We also included search results from the original Cochrane
Review (Shah 2016). We performed the searches with no language
restriction.
Searching other resources
We further examined reference lists of relevant reviews and studies
and searched the WHO website.
Data collection and analysis
Selection of studies
We used Covidence systematic review soRware to manage the
selection of studies (Covidence). The search for this review was
conducted in parallel with the search for the  Cochrane Review
update on the diagnostic accuracy of LF-LAM for tuberculosis
(Bjerrum 2019). Two review authors (MS and SB) working
independently screened titles and abstracts (including those that
were identified in the original Cochrane Review on the diagnostic
accuracy of LF-LAM for tuberculosis (Shah 2016))  to identify
citations that included data on health impact. We retrieved the
article of any citation identified by either review author for full-
text review. Then, two other review authors (RRN and PL) working
independently assessed articles for inclusion using predefined
inclusion and exclusion criteria. In the study selection process, we
assessed the full-texts of the 15 studies included in the Cochrane
Review update, as well as any studies excluded during the full-
text screening (Bjerrum 2019). Any diQerences in opinion were
resolved through discussion. We listed studies excluded aRer full-
text assessment and their reasons for exclusion in a PRISMA flow
diagram (Moher 2009).
Data extraction and management
We developed and piloted a standardized data extraction form.
Subsequently, two review authors (RRN and PL) independently
extracted data from each included study. Any disagreements were
resolved through discussion or by consulting a third review author
(KRS). We extracted data on the following:
• Author, publication year, study design, country(ies), clinical
setting (outpatient or inpatient), number enrolled and analysed.
• Participants: age, HIV status and whether they are taking
antiretroviral therapy, presence of symptoms (symptoms versus
unselected).
• Mode of mortality assessment, type of mortality (all-cause
versus tuberculosis-related), timing of mortality assessment.
• LF-LAM grade and use of old versus new reference card, timing
of LF-LAM.
• Mortality analysis metrics used (risk ratio, absolute risk
reduction, (adjusted) hazard ratio or Kaplan-Meier, (adjusted)
odds ratio).
• Comparator groups analysed.
• Mortality in the intervention group, mortality in the control
group.
• Mortality data stratified by CD4 count.
• Time to diagnosis; time to treatment initiation; time from
diagnosis to treatment initiation.
• Proportion of study participants who were diagnosed with
tuberculosis.
• Proportion of study participants who were treated for
tuberculosis.
• Proportion of study participants who were treated for
tuberculosis and did not have tuberculosis.
• Proportion of study participants who were able to produce a
specimen for diagnostic testing.
• Other outcomes assessed in the study (e.g. incremental
diagnostic yield due to addition of LF-LAM to the diagnostic
algorithm).
• Other tuberculosis-related outcomes (e.g. treatment success or
failure, relapse or cure).
We contacted study authors for clarification as needed.
Assessment of risk of bias in included studies
Two review authors (RRN and PL) independently assessed risk
of bias using the Cochrane tool for assessing risk of bias in
randomized studies (Higgins 2011), employing Review Manager 5
(Review Manager 2020). We contacted the corresponding study
authors for clarification or more information if data were missing
or unclear. Any discrepancies were resolved through discussion or
by consulting a third review author (KRS) if required. We assessed
the included studies for the method of allocation, sequence
generation and allocation concealment, blinding, missing outcome
data, outcome measurement and reporting, and selective reporting
bias. We assessed the risk of bias as low, high, or unclear.
Measures of treatment e<ect
We presented our findings of the eQect of the use of LF-LAM on
dichotomous outcomes using risk ratios or hazard ratios (when
Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV (Review)










Cochrane Database of Systematic Reviews
eQect measure was time-to-event) with respective 95% confidence
intervals.
Unit of analysis issues
We decided that if we identified cluster-RCTs, we would extract
adjusted measures of eQect where possible. If the study authors
did not perform any adjustment for clustering, we would adjust the
raw data using an intraclass correlation coeQicient (ICC) value. If
an ICC value was not reported in the study, we would contact the
study authors for this information, obtain it from similar studies, or
estimate the ICC. We would not present results from cluster-RCTs
that were not adjusted for clustering. If we identified cluster-RCTs,
we would estimate the ICC, and perform sensitivity analyses to
investigate the robustness of our analyses. If we identified studies
for inclusion that had multiple intervention arms, we would include
data from these studies by either combining intervention arms, or
by splitting the control group so that participants would only be
included in the meta-analysis once.
Dealing with missing data
Before extracting data from the studies, we determined the
reasons for missing data by attempting to contact the respective
corresponding study author. We investigated whether the
missingness of data may have introduced attrition bias. We would
carry out an available-case analysis if we considered the missing
data to be missing at random. If we suspected that missing
data were not missing at random, we would perform sensitivity
analyses in which we imputed the data using specific assumptions,
such as assuming all missing participants experienced or did not
experience the event.
Assessment of heterogeneity
We assessed the existence of clinical heterogeneity by examining
diQerences in study characteristics and participant demographic
factors in order to inform decisions regarding the appropriateness
of pooling data from studies in meta-analysis. We assessed
statistical heterogeneity by visually inspecting forest plots and
using a Chi2 test for heterogeneity (with a P value of 0.10 for
significance), and the I2 statistic as a measure of inconsistency
across studies, with an I2 value of 50% higher representing
substantial heterogeneity (Deeks 2021).
Assessment of reporting biases
We planned to assess reporting biases if more than 10 studies
were included in the meta-analysis by examining the funnel plots
visually for symmetry or asymmetry and interpreting test results
in the context of visual inspection of funnel plots. In the case of
asymmetry, we would follow recommendations for interpretation
as recommended by Sterne 2011.
Data synthesis
We conducted analyses using Review Manager 5 (Review Manager
2020). For dichotomous outcomes, we performed meta-analyses
to estimate the pooled risk ratio (95% confidence interval). We
used a fixed-eQect model unless we identified clinical or statistical
heterogeneity, in which case we used a random-eQects model. For
time-to-event outcomes, we would perform meta-analyses to
estimate the pooled hazard ratio (95% confidence interval).
Subgroup analysis and investigation of heterogeneity
Based on data availability, we performed subgroup analyses in
participants with varying CD4 levels, in particular, CD4 > 200 cells/
µL versus CD4 ≤ 200 cells/µL, and CD4 > 100 cells/µL versus CD4
≤ 100 cells/µL. The rationale for subgroup analyses stratified by
CD4 count is because we hypothesized that the use of urine LAM
would have a larger eQect on mortality in participants with lower
CD4 counts, since the diagnostic accuracy of urine LAM is higher
with lower CD4 counts (Bjerrum 2019).
Sensitivity analysis
We planned to perform sensitivity analyses in the case of
circumstances that we thought were likely to influence outcomes,
including the following.
• Excluding studies with missing data that were likely to influence
the outcome.
• Excluding studies with outliers that were suspected to influence
the outcome.
• Excluding studies with high risk of bias that were likely to aQect
the outcome.
Outliers would have been identified on visual examination of forest
plots as  extreme values that we judged important to investigate
the eQect of excluding. None of the included studies had missing
data, outliers, or a high risk of bias  that was likely to influence
the outcome. However, we performed sensitivity analyses in which
we imputed the data using specific assumptions. Based on prior
literature informing the expected tuberculosis mortality at eight
weeks (Ford 2016; Nliwasa 2018), we varied the mortality event rate
in missing participants between 0% and 25%.
Summary of findings and assessment of the certainty of the
evidence
We summarized our findings in the summary of findings tables.
We assessed the certainty of evidence using the GRADE approach
(Hultcrantz 2017), employing GRADEpro GDT soRware (GRADEpro
GDT). We rated each important outcome (primary outcomes) as
described by Balshem 2011, as follows.
• High: we are very confident that the true eQect lies close to that
of the estimate of the eQect.
• Moderate: we are moderately confident in the eQect estimate:
the true eQect is likely to be close to the estimate of the eQect.
• Low: our confidence in the eQect estimate is limited: the true
eQect may be substantially diQerent from the estimate of the
eQect.
• Very low: we have very little confidence in the eQect estimate:
the true eQect is likely to be substantially diQerent from the
estimate of eQect.
Randomized controlled trials start as high-certainty evidence, but
can be downgraded if there are valid concerns within the following
five domains: risk of bias, imprecision, inconsistency, indirectness,
and publication bias. Studies can also be upgraded if there is a
large eQect, a dose-response eQect, and if all plausible residual
confounding would reduce a demonstrated eQect or would suggest
a spurious eQect if no eQect was observed (Balshem 2011).
As recommended, we reported the findings in simple, standardized
statements (Santesso 2020).
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R E S U L T S
Description of studies
We provided descriptions of the included studies in
the Characteristics of included studies and Table 1, 'Characteristics
of studies that evaluated a diagnostic intervention that included
LF-LAM in adults living with HIV'. We provided descriptions of the
excluded studies in Characteristics of excluded studies.
Results of the search
The literature search for this review was conducted in conjunction
with the search for a Cochrane Review update on the diagnostic
accuracy of LF-LAM (Bjerrum 2019). Two studies that were included
by Bjerrum 2019 were identified as meeting the inclusion criteria for
this review (Gupta-Wright 2018; Peter 2016). Our updated searches
identified a further 218 unique studies for title and abstract
screening, two of which met the criteria for full-text review (Blanc
2020; Grant 2020), and one of which met our inclusion criteria to
undergo data extraction (Grant 2020). A flow diagram of the study
selection process is shown in Figure 1.
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Figure 1.   Study flow diagram. The literature search for this review was conducted in conjunction with the search
for a Cochrane Review on the diagnostic accuracy of LF-LAM (AlereLAM) (Bjerrum 2019). We initially identified 189
studies for title and abstract screening, of which 41 were selected for full-text review. FiKeen studies were identified
for Bjerrum 2019, and two studies were identified for this review. Updated literature searches on 12 November 2019
and 12 March 2021 identified one additional study. *In this study, the standard-of-care arm utilized a diagnostic
strategy that did not include any of the tuberculosis tests described in our protocol as criteria for inclusion, and the
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study was not used to guide clinical decision-making, precluding comparison of the impact of LF-LAM compared to
other diagnostic strategies (Blanc 2020).
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Included studies
We included  three studies that assessed the impact of LF-
LAM on mortality when the test was used for clinical decision-
making;  two of these took place in inpatient settings (Gupta-
Wright 2018; Peter 2016), and one in outpatient settings (Grant
2020). Both inpatient studies were multisite RCTs conducted in sub-
Saharan African countries that evaluated the impact of a diagnostic
strategy that included LF-LAM as a tuberculosis diagnostic test
to guide treatment initiation in HIV-positive adults, comparing
all-cause mortality at 56 days (eight  weeks)  between the LF-
LAM intervention arm and standard-of-care control arm (Gupta-
Wright 2018; Peter 2016). The outpatient study was an open-label
cluster-RCT conducted in South Africa that evaluated the impact
of a diagnostic strategy that included LF-LAM as a tuberculosis
diagnostic test to guide treatment initiation in people living with
HIV, comparing all-cause mortality at six months between the LF-
LAM intervention arm and standard-of-care control arm (Grant
2020). None of the trials  reported  the cause of death, including
tuberculosis-related mortality.
Important dierences between the trials evaluating the impact
of LF-LAM on mortality
There were several diQerences between the trials. Although both
of the trials in inpatient settings were multisite studies,  Peter
2016  took place at 10 sites across four countries (South Africa,
Tanzania, Zambia, Zimbabwe), whilst  Gupta-Wright 2018  was
conducted at two sites in two countries (South Africa and
Malawi). Gupta-Wright 2018 screened patients admitted to medical
wards, and Peter 2016 screened patients admitted to emergency
units and short-stay wards, in addition to medical wards. In Peter
2016, a trained nurse conducted the LF-LAM testing at the bedside
and reported the LF-LAM result to the clinical team along with
a recommendation regarding treatment based on the results,
whilst in  Gupta-Wright 2018, all LF-LAM testing as well as Xpert
MTB/RIF was conducted within the laboratory and reported as
a combined tuberculosis screening result (i.e.  positive,  negative,
not done (combined for all tuberculosis screening tests performed
rather than only for the individual LF-LAM result)). The intervention
in  Gupta-Wright 2018  included LF-LAM and urine Xpert MTB/
RIF, thus the impact of LF-LAM cannot be separated from urine
Xpert MTB/RIF, although the authors note that of the patients
with microbiologically confirmed tuberculosis, the diagnostic yield
from LF-LAM was 75% (158/210) compared to 35% (74/210) for
urine Xpert MTB/RIF and 40% (85/210) for sputum Xpert MTB/
RIF. The median CD4 count was lower in  Peter 2016  compared
to  Gupta-Wright 2018  (84 cells/µL versus 227 cells/µL). This, in
addition to lower body mass index (BMI) and Karnofsky scores,
suggests that the population evaluated in the Peter 2016 study may
have been sicker. Overall severity of illness was higher in  Peter
2016  (mortality 21% in LF-LAM and 25% in no LF-LAM arms)
compared to Gupta-Wright 2018 (mortality 18% in LF-LAM and 21%
in no LF-LAM arms). The percentage of participants on antiretroviral
therapy was lower in Peter 2016 than in Gupta-Wright 2018 (48%
versus 72%). A greater proportion of participants were started on
tuberculosis treatment in  Peter 2016  compared to  Gupta-Wright
2018 (50% versus 17%), likely reflecting diQerent inclusion criteria
(clinical suspicion of tuberculosis in the former compared with
an unselected population irrespective of symptoms in the latter)
and a consequent diQerence in the severity of illness in the study
populations between the two trials. Despite these diQerences, we
considered the interventions implemented, target population, and
study setting to be suQiciently similar in both inpatient trials to
permit pooling in a meta-analysis.
The outpatient trial was conducted at 24 primary healthcare
clinics in South Africa (Grant 2020). In  Grant 2020, study
nurses at intervention clinics assessed patients using a
multifactorial assessment, consisting of tuberculosis symptoms,
BMI, point-of-care haemoglobin concentrations, and urine LF-
LAM results. A positive urine LF-LAM result was one of the
high probability criteria defined in the study algorithm which
categorized participants as high probability of tuberculosis, for
which initiation of tuberculosis treatment was recommended
immediately followed by antiretroviral treatment two weeks later,
versus medium probability of tuberculosis, for which symptom-
guided investigation was recommended, versus low probability of
tuberculosis, for which initiation of antiretroviral treatment was
recommended. Although this trial was conducted in outpatient
settings, where participants are typically expected to be less sick
than in inpatient settings, the eligibility criteria included having
a CD4 count of 150 cells/µL or less, and the median CD4 count
was lower than in the two inpatient trials (72 cells/µL). Most
participants (69%) were symptomatic, although this was not part
of the eligibility criteria. Individuals with clinical signs necessitating
urgent referral to secondary care were excluded.
Excluded studies
We excluded eight full-text articles from the literature searches
performed up to 12 March 2021. We excluded seven of these studies
because they were not RCTs (Cummings 2019; Gupta-Wright 2019;
Huerga 2019; Kubiak 2018; Mathabire Rucker 2019; Mthiyane 2019;
Naidoo 2019). We excluded one study because the standard-of-
care arm utilized a diagnostic strategy that did not include any of
the tuberculosis tests that we described in our protocol criteria
for inclusion, and was not used to guide clinical decision-making,
precluding comparison of the impact of LF-LAM to other diagnostic
strategies (Blanc 2020).
Risk of bias in included studies
The assessment of risk of bias in the included studies is shown in
Figure 2 and Figure 3.
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Grant 2020 + + ? ? + + +
Gupta-Wright 2018 + + + + + + ?
Peter 2016 + + ? ? + + ?
 
Allocation
Gupta-Wright 2018 and Peter 2016 used random sequence
generation and were thus assessed as at low risk of selection bias in
this domain, and were also judged to be at low risk of selection bias
with respect to allocation concealment. In Peter 2016, participants
were assigned to the intervention arm which included LF-LAM
versus standard-of-care using computer-generated allocation lists.
Research nurses who did not have access to these lists either
contacted a data manager by telephone or used a text message
system to assign each participant. In Gupta-Wright 2018, study
nurses or clinicians took a consecutive sealed envelope which
contained the unique patient identifier but did not reveal the
study group, to which they remained masked. In Grant 2020,
randomization at the clinic level was performed by a study
Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV (Review)










Cochrane Database of Systematic Reviews
statistician to achieve reasonable balance, taking into account
mean CD4 count, peri-urban versus rural clinic location, and total
monthly antiretroviral therapy initiations.
Blinding
We judged two studies to have an unclear risk of both performance
and detection bias because participants and research staQ in Peter
2016 and Grant 2020, and clinic staQ in Grant 2020, were not
masked to either allocation or test results, and it is unclear how this
lack of blinding may have aQected clinical decision-making. Since
investigators, all study staQ (other than the laboratory technician
and statistician), hospital attending clinical teams, and participants
were masked to the study group allocation in Gupta-Wright 2018,
we judged this trial to be at low risk of bias.
Incomplete outcome data
We judged all three studies to have a low risk of attrition bias due
to incomplete outcome data, reporting a 5% loss to follow-up rate
(Peter 2016); 1% loss to follow-up rate (Gupta-Wright 2018); and 0%
loss to follow-up rate (Grant 2020), respectively.
Selective reporting
We judged all three studies to have a low risk of reporting bias, as
they prespecified their primary and secondary outcome measures
in clinical trial registries (ClinicalTrials.gov ID: NCT01770730 (Peter
2016), ISRCTN ID: ISRCTN71603869 (Gupta-Wright 2018), and
ISRCTN ID: ISRCTN35344604 and number DOH-27-0812-3902 in the
South African National Clinical Trials Register (Grant 2020)).
Other potential sources of bias
We judged the two studies in inpatient settings to have an unclear
risk of other bias (Peter 2016; Gupta-Wright 2018). The informed
consent requirements for both inpatient trials may have resulted
in the exclusion of people who were critically ill, who would have
been part of the target population for the intervention in real-
world practice settings. Similarly, limiting enrolment to standard
working hours and for less than 48 hours aRer admission may have
also introduced other bias. Peter 2016 also noted a heterogeneous
mortality eQect across the four countries in which the study
was conducted. We judged  Grant 2020  to have a low risk of
other bias because although there were some diQerences between
the intervention and standard-of-care groups, notably presence
of tuberculosis symptoms, prior receipt of isoniazid preventive
therapy, and receipt of tuberculosis tests in the preceding six
months, we did not think these diQerences were likely to introduce
bias.
E<ects of interventions
See: Summary of findings 1 EQect of LF-LAM compared to no LF-
LAM on mortality and tuberculosis treatment initiation in people
living with HIV, inpatient settings; Summary of findings 2 EQect
of LF-LAM compared to no LF-LAM on mortality and tuberculosis
treatment initiation in people living with HIV, outpatient settings
Impact of LF-LAM on mortality in inpatient settings
Both included trials assessed mortality at eight weeks. The pooled
risk ratio (RR) was 0.85 (95% confidence interval (CI) 0.76 to
0.94;  5102 participants, 2 trials,  Analysis 1.1,  Figure 4). That is,
people living with HIV who received LF-LAM had 15% lower risk of
mortality. The absolute eQect was 34 fewer deaths per 1000 (from
14 fewer to 55 fewer) (moderate-certainty evidence) (Summary of
findings 1).
 
Figure 4.   Forest plot comparing the risk ratios for mortality in participants in inpatient settings who received
a diagnostic intervention including LAM compared to those who received standard of care (SoC). Mortality was
assessed at eight weeks in Gupta-Wright 2018 and Peter 2016. Between brackets are the 95% confidence intervals
(CI) for the risk ratios. The figure shows the estimated mortality risk ratio for each study (blue square) and its 95% CI
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Owing to a 5% loss to follow-up rate in  Peter 2016  with the
possibility of potentially unbalanced study arms, we performed
sensitivity analyses to investigate the robustness of the available-
case analyses. The pooled RR was 0.87 (95% CI 0.78 to 0.97) with
a 25% mortality event rate in the intervention compared to 0%
event rate in the standard-of-care group (Analysis 1.2,  Figure 5),
and 0.82 (95% CI 0.74 to 0.91) with a 0% mortality event rate in
the intervention compared to 0% event rate in the standard-of-
care group (Analysis 1.3, Figure 6). We thus found that the overall
meta-analysis result remained statistically significant regardless of
varying the hypothetical event rate amongst missing data, and we
can therefore be confident in our overall finding.
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Figure 5.   Forest plot comparing the risk ratios for mortality at eight weeks in participants in inpatient settings who
received a diagnostic intervention including LAM compared to those who received standard of care (SoC), sensitivity
analysis with 25% mortality in missing participants receiving LAM and 0% mortality in missing participants
receiving SoC. Between brackets are the 95% confidence intervals (CI) for the risk ratios. The figure shows the
estimated mortality risk ratio for each study (blue square) and its 95% CI (black horizontal line) and the pooled
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Figure 6.   Forest plot comparing the risk ratios for mortality at eight weeks in participants in inpatient settings who
received a diagnostic intervention including LAM compared to those who received standard of care (SoC), sensitivity
analysis with 0% mortality in missing participants receiving LAM and 25% mortality in missing participants
receiving SoC. Between brackets are the 95% confidence intervals (CI) for the risk ratios. The figure shows the
estimated mortality risk ratio for each study (blue square) and its 95% CI (black horizontal line) and the pooled
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Impact of LF-LAM on mortality in outpatient settings
The one included trial assessed mortality at six months. The RR
was 0.89 (95% CI 0.71 to 1.11; 2972 participants, 1 trial,  Analysis
1.4,  Figure 7; Summary of findings 2). Although this trial did not
detect a diQerence in mortality at six months in people living with
HIV who had received  LF-LAM testing as part of a tuberculosis
diagnostic strategy compared to routine tuberculosis diagnostic
testing without LF-LAM, the direction of eQect was  towards  a
mortality reduction, and similar to the eQect in people evaluated in
inpatient settings.
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Figure 7.   Forest plot reporting the risk ratio for mortality at six months in participants in outpatient settings who
received a diagnostic intervention including LAM compared to those who received standard of care (SoC). Between
brackets are the 95% confidence intervals (CI) for the risk ratios. The figure shows the estimated mortality risk ratio
for each study (blue square) and its 95% CI (black horizontal line) and the pooled estimated mortality risk ratio
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Impact of LF-LAM on mortality in inpatient settings with CD4 ≤
100 cells/µL versus CD4 > 100 cells/µL
Analysis 2.1  examines  the impact of LF-LAM on mortality in
individuals in inpatient settings stratified by CD4 count with a
threshold of 100 cells/µL. Table 2 demonstrates the heterogeneity
in eQect estimates across CD4 strata that were seen within and
between the two included trials.
For individuals with a CD4 count of ≤ 100 cells/µL, the pooled RR
was 0.88 (95% CI 0.77 to 1.01; 2016 participants, 2 trials, Analysis
2.1.1, subgroup 1, Figure 8).
 
Figure 8.   Forest plot comparing the risk ratios for mortality in inpatients who received a diagnostic intervention
including LAM compared to those who received standard of care (SoC), mortality at eight weeks, by CD4 strata ≤ 100
cells/µL versus > 100 cells/µL. Between brackets are the 95% confidence intervals (CI) for the risk ratios. The figure
shows the estimated mortality risk ratio for each study (blue square) and its 95% CI (black horizontal line) and the
pooled estimated mortality risk ratio combining results from both studies (black diamond).
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For individuals with a CD4 count of > 100 cells/µL, the pooled RR
was 0.80 (95% CI 0.55 to 1.17; 2867 participants, 2 trials, Analysis
2.1.2, subgroup 2, Figure 8).
Given that the I2 statistic for  Analysis 2.1.2 demonstrated
substantial heterogeneity, we used a random-eQects model for
these meta-analyses.
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Impact of LF-LAM on mortality in inpatient settings with CD4 ≤
200 cells/µL versus CD4 > 200 cells/µL
Analysis 2.2  examines the impact of LF-LAM on mortality in
individuals in inpatient settings  stratified by CD4 count with a
threshold of 200 cells/µL.  Table 2 demonstrates the heterogeneity
in eQect estimates across CD4 strata that were seen within and
between the two included trials.
For individuals with a CD4 count of ≤ 200 cells/µL, the pooled RR
was 0.87 (95% CI 0.77 to 0.98; 2886 participants, 2 trials, Analysis
2.2.1, subgroup 1, Figure 9).
 
Figure 9.   Forest plot comparing the risk ratios for mortality in inpatients who received a diagnostic intervention
including LAM compared to those who received standard of care (SoC), mortality at eight weeks, by CD4 strata ≤ 200
cells/µL versus > 200 cells/µL. Between brackets are the 95% confidence intervals (CI) for the risk ratios. The figure
shows the estimated mortality risk ratio for each study (blue square) and its 95% CI (black horizontal line) and the
pooled estimated mortality risk ratio combining results from both studies (black diamond).
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For individuals with a CD4 count of > 200 cells/µL, the pooled RR
was 0.77 (95% CI 0.48 to 1.23; 2017 participants, 2 trials, Analysis
2.2.2, subgroup 2, Figure 9).
Given that the I2 statistic for  Analysis 2.2.2 demonstrated
substantial heterogeneity, we used a random-eQects model for
these meta-analyses.
Impact of LF-LAM on mortality in outpatient settings with CD4
< 50 cells/µL versus CD4 ≥ 50 cells/µL
Analysis 2.3  examines the impact of LF-LAM on mortality in
outpatient settings stratified by CD4 count with a threshold of 50
cells/µL.
For individuals with a CD4 count of < 50 cells/µL, the RR was
1.01 (95% CI 0.78 to 1.31, 460 person-years, 1 trial, Analysis 2.3.1,
subgroup 1), that is a detectable diQerence in mortality was not
seen in study participants with a CD4 count of < 50 cells/µL who
received a diagnostic assessment that included LF-LAM testing
compared to those undergoing standard of care without LF-LAM.
For individuals with a CD4 count of ≥ 50 cells/µL, the RR was
0.76 (95% CI 0.55 to 1.05, 942 person-years, 1 trial, Analysis 2.3.2,
subgroup 2), that is the direction of eQect was towards a decrease
in mortality in study participants with a CD4 count of ≥ 50 cells/µL
who received a diagnostic assessment that included LF-LAM testing
compared to those undergoing standard of care without LF-LAM.
Other patient-important and implementation outcomes
Although mortality was the primary patient-important outcome
of interest, we also recorded data on other patient-important
outcomes. However, data for our prespecified secondary outcomes
were oRen not reported or were analysed variably between studies,
which limited our ability to perform meta-analyses.
Time to diagnosis, time to tuberculosis treatment initiation,
and time from diagnosis to tuberculosis treatment initiation
Gupta-Wright 2018  found that the time from randomization to
diagnosis was marginally shorter in the LF-LAM intervention
group compared to the standard-of-care group (median 0 days
(interquartile range (IQR) 0 to 1)) versus 1 day (IQR 0 to 6), adjusted
hazard ratio 1.55 (95% CI 1.29 to 1.87). Time from diagnosis to
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treatment was short (median 1 day (IQR 0 to 1)) and did not diQer
between the group that received LF-LAM and the standard-of-care
group (adjusted hazard ratio 0.83, 95% CI 0.69 to 1.01).
Peter 2016 reported that time-to-treatment initiation in the group
that received LF-LAM was shorter than in the group that did not
receive LF-LAM, with a higher proportion of those treated having
antituberculosis treatment initiated by the end of days 1 to 4 of
hospitalization (84% versus 76%, P < 0.001).
Proportion of study participants who were diagnosed with
tuberculosis
Gupta-Wright 2018  reported that increases in tuberculosis
diagnoses in the intervention group that received LF-LAM (22% of
tuberculosis diagnoses) compared to the standard-of-care group
(15% of tuberculosis diagnoses) were not confined to high-risk
subgroups, with an overall adjusted absolute risk diQerence of 7.3%
(95% CI 4.4 to 10.2). These results were adjusted for study sites;
unadjusted data were not provided.
Proportion of study participants who were treated
for tuberculosis
In inpatient settings, both included trials assessed tuberculosis
treatment initiation. The pooled RR was 1.26 (95% CI 0.94  to
1.69;  5102 participants, 2 trials,  Analysis 3.1,  Figure 10).  Of note
the, I2 statistic (90%) suggested substantial heterogeneity, thus
we used random-eQects meta-analysis. We hypothesize that this
heterogeneity  was due to the smaller diQerence between the
proportion of participants initiated on treatment for the group
that received the diagnostic intervention that included LF-LAM
compared to the standard-of-care group that did not receive LF-
LAM in Peter 2016 compared to Gupta-Wright 2018. This diQerence
is likely reflective of the population  in  Peter 2016  being sicker,
resulting in  a higher likelihood of empiric treatment even in the
standard-of-care group, compared to Gupta-Wright 2018, in which
participants were enrolled irrespective of symptoms and signs of
tuberculosis and were less sick (Table 1).
 
Figure 10.   Forest plot comparing the risk ratios for proportion of participants in inpatient settings treated for
tuberculosis who received a diagnostic intervention including LAM compared to those who received standard of care
(SoC). Between brackets are the 95% confidence intervals (CI) for the risk ratios. The figure shows the proportion
for each study (blue square) and its 95% CI (black horizontal line) and the pooled estimated mortality risk ratio
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In outpatient settings, the included trial assessed tuberculosis
treatment initiation. The RR was 5.44 (95% CI 4.70 to 6.29, 3022
participants, 1 trial, Analysis 3.2, Figure 11).
 
Figure 11.   Forest plot reporting the risk ratio for proportion of participants in outpatient settings treated for
tuberculosis who received a diagnostic intervention including LAM compared to those who received standard of care
(SoC). Between brackets are the 95% confidence intervals (CI) for the risk ratios. The figure shows the proportion for
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Proportion of study participants who were treated for
tuberculosis but did not have tuberculosis
None of the included trials evaluated the proportion of study
participants who were treated for tuberculosis but did not have
tuberculosis.
Proportion of participants who were able to produce a
specimen for diagnostic testing
Both inpatient trials reported that a higher proportion of study
participants were able to provide urine as a diagnostic specimen
compared to sputum. Gupta-Wright 2018 reported that urine was
provided by 99% (2548/2574) of participants, whereas only 57%
(1464/2574) were able to produce sputum. Of note, the proportion
of participants able to produce sputum in Malawi (39%, 518/1316)
was lower than in South Africa (75%, 946/1258). Peter 2016 similarly
reported that 99% (2507/2528) were able to produce a urine
specimen; however, in this study 93% (2355/2528) were able to
produce a sputum specimen for diagnosis. We believe that this
heterogeneity between studies may reflect the enrolment of a
population with a higher burden of pulmonary disease in  Peter
2016, or study operational factors such as  improved counselling
regarding specimen collection or the availability and use of sputum
induction for participants who were unable to produce sputum
spontaneously in Peter 2016. In contrast, only a single spontaneous
sputum specimen was collected in Gupta-Wright 2018.
Incremental diagnostic yield due to addition of LF-LAM to the
diagnostic algorithm
Gupta-Wright 2018  reported that increases in tuberculosis
diagnoses in the intervention group that received LF-LAM (22% of
tuberculosis diagnoses) compared to the standard-of-care group
(15% of tuberculosis diagnoses) were not confined to high-risk
subgroups, with an overall adjusted absolute risk diQerence of 7.3%
(95% CI 4.4 to 10.2). These results were adjusted for study sites;
unadjusted data were not provided. Gupta-Wright 2018  reported
that of participants with microbiologically confirmed tuberculosis
who had only one positive LF-LAM test, LF-LAM had an incremental
diagnostic yield of 41% (87/210), compared to 6% (13/210) for urine
Xpert MTB/RIF and 14% (30/210) for sputum Xpert MTB/RIF.
Tuberculosis-related treatment outcomes (treatment success
or failure, relapse or cure)
None of the included trials evaluated other tuberculosis-related
treatment outcomes (treatment success or failure, relapse or cure).
D I S C U S S I O N
Summary of main results
Two trials in inpatient settings and one trial in outpatient settings
assessed the impact of diagnostic strategies that included LF-LAM
on mortality when the test was used in conjunction with other
tuberculosis diagnostic tests or clinical assessment for clinical
decision-making in people living with HIV (see Summary of findings
1  and  Summary of findings 2). In inpatient settings, the use
of LF-LAM testing as part of a tuberculosis diagnostic strategy
likely reduces mortality in people living with HIV at eight weeks
compared to routine tuberculosis diagnostic testing without LF-
LAM (moderate-certainty evidence). Although the certainty of the
evidence is moderate, this finding represents a moderate  eQect
on a patient important outcome (mortality) and in an important
population (people living with HIV) that is aligned with the decision
of the WHO Guideline Development Group, which issued a "strong
recommendation for the intervention" in the inpatient context
(WHO Consolidated Guidelines (Module 3) 2020). In outpatient
settings, the use of LF-LAM testing as part of a tuberculosis
diagnostic strategy may reduce mortality in people living with HIV
at six months compared to routine tuberculosis diagnostic testing
without LF-LAM (low-certainty evidence). Although this trial did not
detect a diQerence in mortality, the direction of eQect was towards
a mortality reduction, and the eQect size was similar to that in
inpatient settings.
Assessment of other patient-important and implementation
outcomes in the trials varied. In inpatient settings, the use of LF-
LAM testing as part of a tuberculosis diagnostic strategy probably
results in a slight increase in the proportion of people living with HIV
who were started on tuberculosis treatment compared to routine
tuberculosis diagnostic testing without LF-LAM. In outpatient
settings, the use  of LF-LAM testing as part of a tuberculosis
diagnostic strategy may result in a large increase in the proportion
of people living with HIV who were started on tuberculosis
treatment compared to routine tuberculosis diagnostic testing
without LF-LAM. The included trials demonstrated that a higher
proportion of people living with HIV were able to produce
urine compared to sputum for tuberculosis diagnostic testing;
a higher proportion of people living with HIV were diagnosed
with tuberculosis in the group that received LF-LAM; and the
incremental diagnostic yield was higher for LF-LAM than for urine
or sputum Xpert MTB/RIF.
Overall completeness and applicability of evidence
The three included trials were conducted in sub-Saharan Africa,
thus  we do not have direct evidence of the applicability of the
findings to other settings outside of Africa. Although the majority of
people with HIV-associated tuberculosis live in sub-Saharan Africa,
caution is required with respect to inferences to policy from the
limited number of trials conducted to date. Although the only
outpatient trial, Grant 2020, was conducted at multiple clinics in
one country (South Africa), both inpatient trials included more
than one country, and Peter 2016  included four countries, which
increases the applicability of the study findings to settings outside
of South Africa, which is important because other countries in sub-
Saharan Africa are more resource-constrained than South Africa.
We emphasize  the importance of the finding that despite
diQerences in study design, two large,  multicentre trials
demonstrated that the use of LF-LAM reduced mortality in inpatient
settings, which increases  generalizability.  In  Gupta-Wright 2018,
the test was performed in the laboratory, not at the point of care.
The intervention in Gupta-Wright 2018 was a combination of LF-
LAM and urine Xpert MTB/RIF, which could impact generalizability,
and introduces heterogeneity since it is not possible to assess the
impact of LF-LAM alone in this study. In Peter 2016, the intervention
was bedside LF-LAM plus a "nurse-informed" treatment decision.
In Grant 2020, the intervention was a study nurse-led diagnostic
evaluation that included assessment of tuberculosis symptoms,
BMI, fingerprick haemoglobin testing, and point-of-care LF-LAM
testing. There was heterogeneity in the inpatient trial populations
in that Gupta-Wright 2018 screened patients admitted to medical
wards, and Peter 2016 screened patients admitted to emergency
units, short-stay wards, and medical wards. This may have biased
the study populations to being sicker, particularly if this led to
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an earlier time of enrolment in  Peter 2016, although both trials
only enrolled patients admitted for less than 48 hours. We note
that the informed consent requirements for both inpatient trials
likely resulted in the exclusion of patients who were critically
ill, and that enrolment being limited to standard working hours
and for less than 48 hours aRer admission may have aQected
the representativeness of the population studied.  In Grant 2020,
patients who met criteria for urgent referral to secondary care were
excluded, as were patients with a higher risk of adverse events
due to tuberculosis treatment, specifically those with chronic liver
disease or high weekly alcohol intake.
These additional considerations may not reflect how the test
will be performed in routine practice in other clinical settings.
Important questions related to implementation remain, such as
how diagnostic algorithms will be implemented to identify patients
to undergo LF-LAM testing; what is the impact of LF-LAM being
performed at the bedside by staQ who may be less familiar with
the challenges of interpreting the results based on the reference
scale card versus in the laboratory by trained staQ; and how will
LF-LAM results be acted upon, particularly in the clinical scenario
where the LF-LAM test is positive, and another test such as Xpert
is negative. The relatively low accuracy of the current LF-LAM test
may compromise its impact, depending upon how it is interpreted
by the end-users of the test, for example if a negative LF-LAM test
is interpreted as the absence of tuberculosis. We await studies
that evaluate the impact of more accurate urine LAM tests, such
as FujiLAM (Broger 2020), on mortality and patient-important
outcomes.
The only trial evaluating the impact of LF-LAM in outpatient settings
did not demonstrate an eQect on mortality, although the direction
of eQect was towards a mortality reduction, and the eQect size was
similar to that in inpatient settings. However, we do not consider
that inpatient status should necessarily be a limiting factor for
test use. We note that people with HIV presenting in outpatient
settings with tuberculosis may be very sick, which aligns with
the WHO's conditional recommendation for the use of LF-LAM in
this population. We also emphasize that mortality is not the only
patient-important outcome to be considered. Results from all three
trials included in this review demonstrated an increase or direction
of eQect towards an increase in tuberculosis treatment initiation
amongst people who received a diagnostic strategy that included
LF-LAM, which is an important implementation outcome as part of
eQorts to improve the quality of tuberculosis care.
Potential explanations for heterogeneity in e<ect estimates
across CD4 strata
We hypothesized that eQect estimates may vary between CD4
strata (summarized in Table 2 for the inpatient trials Gupta-Wright
2018 and Peter 2016) owing to factors that could lead to either a
reduced or improved eQect size for participants with CD4 ≤ 100
cells/µL or CD4 ≤ 200 cells/µL, compared to CD4 > 100 cells/µL
or CD4 > 200 cells/µL, respectively. Similarly, the results for Grant
2020  summarized in  Analysis 2.3  demonstrate that CD4 count
may be associated with both LF-LAM positivity, and mortality
(i.e. it can serve simultaneously as a covariate of interest and
outcome). CD4 count could also be associated with antiretroviral
therapy (ART) usage, and empiric tuberculosis treatment initiation.
Consequently, these factors could impact the eQect of any benefit
from earlier diagnosis (e.g. through LF-LAM implementation) and
lead to variable eQects (of LF-LAM implementation). For example, if
in both study arms participants with a lower CD4 were more likely
to start tuberculosis treatment (which would be done empirically in
the standard-of-care arm), then the benefit of confirmed diagnosis
by LF-LAM could be blunted. Conversely, individuals with lower
CD4 are more likely to have LF-LAM positivity leading to earlier
treatment diagnosis and initiation. LF-LAM compared to standard
of care could therefore have reduced mortality. LF-LAM positivity
is also associated with mortality (Gupta-Wright 2016; Shah 2016).
Consequently, earlier diagnosis through LF-LAM may not lead to a
modifiable outcome, since having a lower CD4 count is associated
with an increased risk of mortality (Kaplan 2018). LF-LAM positivity
may also serve as a surrogate for a point-of-care CD4 test, thus
LAM positivity could have stimulated earlier ART initiation (which
may have a mortality benefit) if it is interpreted as a CD4 proxy.
LF-LAM may also be a marker of bacterial load (Shah 2010), and
treatment may thus have diQerential impact amongst people with
tuberculosis who have a positive LF-LAM test compared to people
with tuberculosis who have a negative LF-LAM test, but neither
included study compared mortality in participants with a positive
versus negative LF-LAM test.
Understanding whether the use of LF-LAM testing has a diQerential
impact on mortality at lower CD4 counts is clinically relevant
given the higher overall risk of tuberculosis-related mortality
in these subgroups. Since the results from individual studies
were heterogeneous within CD4 strata, and neither inpatient trial
reported mortality rates by CD4 strata, evidence to explain how
the eQectiveness of the use of LF-LAM may vary according to CD4
count is uncertain. However, the subgroup analyses demonstrated
that the direction of eQect was towards decreased mortality for all
CD4 strata examined, and that the eQect did not vary significantly
between diQerent CD4 subgroups, aside from CD4 count < 50 cells/
µL in the trial that was conducted in outpatient settings (Grant
2020).
Analysis of subgroup data, particularly those stratified by CD4
count, is limited, since the trials were not powered to detect
changes at the subgroup level. Consequently,  these results must
be interpreted with caution when considering how the  impact of
the use of LF-LAM may vary according to CD4 count. Despite
some diQerences in the pooled eQect estimates across CD4
strata, these diQerences were not statistically significant, and
the direction of the pooled eQect estimates was towards a
decrease in mortality for each CD4 stratum, aside from CD4
count < 50 cells/µL in  Grant 2020.  CD4 subgroup analysis
results may not have reached statistical significance owing
to the association of lower CD4 count with both LF-LAM
positivity and mortality. LF-LAM positivity is also associated with
increased mortality, thus LF-LAM-directed treatment may have
been insuQicient to avert the increased mortality associated with
LF-LAM positivity.  Understanding whether there is a diQerence
in treatment outcomes amongst those who have a positive LF-
LAM result compared to a negative LF-LAM result, adjusting for
time of tuberculosis treatment, ART usage, and CD4 count may be
important for future LAM implementation.
Secondary implementation outcomes
Analysis of secondary outcome data should also be interpreted
with caution, given the substantial heterogeneity between the
three trials. The diQerences in these secondary outcomes, including
time to treatment initiation and likelihood of being able to
produce a specimen for tuberculosis diagnostic testing, may reflect
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the diQerent severity of illness in the study populations.  Peter
2016  included people with signs and symptoms of tuberculosis,
whereas Gupta-Wright 2018  included people irrespective of signs
and symptoms of tuberculosis. It is likely that enrolment of a
sicker population  in  Peter 2016  resulted in more individuals in
both arms being started on tuberculosis treatment. It may be
that sicker individuals in  Peter 2016  had a higher burden of
respiratory disease that resulted in a higher proportion being able
to produce a sputum specimen, or other operational factors such as
potentially improved counselling related to specimen production
may have increased the feasibility and yield of sputum-based
testing. Similarly, although Grant 2020 was performed in outpatient
settings, the median CD4 count was lower than for the two trials
performed in inpatient settings, which likely resulted in more
people being started on tuberculosis treatment.
Other implementation considerations
This review evaluated the impact of LF-LAM to guide treatment
decisions in the context of clinical trials. Further implementation
research is needed to assess the reach, eQectiveness, costs,
and other operational considerations during programmatic
implementation.
Quality of the evidence
Details regarding the downgrading of the certainty of the
evidence using the GRADE approach are included in the summary
of findings tables. Our main reason  for downgrading the
certainty of the evidence for the analysis of trials in inpatient
settings was  indirectness, a concern about the generalizability to
other settings due to heterogeneity in the diagnostic strategy used
(aside from the use of LF-LAM) owing to the use of a pragmatic trial
design. In both trials, patients who could not give informed consent
were ineligible to participate, which may have biased the eQect of
the intervention towards the null if sicker patients were less likely
to be able to give informed consent. Our reasons for downgrading
the certainty of the evidence for the analysis of trials in outpatient
settings were concerns about indirectness, given that only one trial,
conducted in South Africa, was included, and imprecision, based on
the wide 95% confidence interval that was reported.
Potential biases in the review process
We were careful to limit bias in the review process by strict
adherence to Cochrane methods. Since policymakers, clinicians,
and members of the wider tuberculosis community considered this
review to be critical to decision-making, we included subgroup
analyses by CD4 count, even though only three trials were identified
for inclusion in the review, and we specified these analyses a
priori in our protocol. We advise that results from these subgroup
analyses  be interpreted with caution given the small number of
studies and residual heterogeneity between results of individual
studies analysed according to CD4 count. However,  the selection
of CD4 count was also motivated by biological and clinical
considerations, and we note that both inpatient trials contributed
more than 2000 participants to each CD4 strata analysed.
Agreements and disagreements with other studies or
reviews
We are not aware of other systematic reviews  on this topic.
A systematic review that sought to evaluate the prognostic
value of LF-LAM to determine mortality risk demonstrated that
the detection of LF-LAM in urine was independently associated
with increased risk of mortality during treatment, aRer adjusting
for other factors associated with mortality (Gupta-Wright 2016).
Another  recent study evaluating the implementation of LF-LAM
(excluded from this review  due its observational study design)
found that LAM-positive patients not diagnosed through other
tools and not treated for tuberculosis had a significantly higher
risk of mortality compared to LAM-positive patients who received
treatment  (Huerga 2019). This is consistent with our explanation
of the heterogeneity in eQect estimates observed across CD4
strata, which we hypothesized may reflect the increased mortality
associated with LF-LAM positivity, although the studies included in
our review did not specifically evaluate mortality in patients who
had a LF-LAM positive test compared to those who had a LF-LAM
negative test. Our review is the only systematic review to assess the
impact of using a diagnostic testing strategy that includes the use
of LF-LAM to guide management decisions on mortality and other
patient-important outcomes.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In inpatient settings, the use of LF-LAM as part of a tuberculosis
diagnostic testing strategy likely reduces mortality and probably
results in a slight increase in tuberculosis treatment initiation in
people living with HIV. The reduction in mortality is likely due
to earlier diagnosis, which facilitates prompt treatment initiation.
In outpatient settings, the use of LF-LAM testing as part of a
tuberculosis diagnostic strategy may reduce mortality and may
result in a large increase in tuberculosis treatment initiation in
people living with HIV. Our results support the implementation of
LF-LAM to be used in conjunction with other WHO-recommended
tuberculosis diagnostic tests to assist in the rapid diagnosis of
tuberculosis in people living with HIV.
Implications for research
Given the limited number of trials on this topic, there is less
certainty in the eQect estimates for the subgroup analyses
stratified by CD4 count, which reflects a patient population of
clinical importance. Additional studies will help to understand
the heterogeneity demonstrated in eQect estimates across CD4
strata and to determine the impact of LF-LAM testing on mortality
and patient-important outcomes in outpatient populations. There
is also an urgent need for studies evaluating the eQect of LF-
LAM on patient-important outcomes in children. Further studies
are needed to understand the impact of new, urine-based, point-
of-care tests that detect urine LAM for tuberculosis diagnosis,
such as the FujiLAM assay, on mortality and patient-important
outcomes that inform the use of LAM assays on both diagnostic and
treatment pathways. The use of implementation science research
can strengthen the evidence base to inform  the  adoption of
interventions such as LF-LAM by health systems.
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Participants 3022 HIV-positive adults, outpatients
Interventions Composite clinical assessment including tuberculosis symptoms, BMI, haemoglobin concentration,
and urine LAM result
Outcomes Mortality
Notes Mortality assessed at 6 months.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A statistician randomised primary health-care clinics (1:1), using com-




Low risk Quote: "A statistician randomised primary health-care clinics (1:1), using com-
puter-generated random numbers, to the intervention or standard of care
(control), based on restriction to achieve reasonable balance, separately, for






Unclear risk Quote: "Due to the nature of the intervention being examined, participants, re-
search staQ, and clinic staQ were aware of group allocation."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Quote: "To ascertain possible serious and severe adverse events... research
nurses and research assistants enquired about symptoms and history sug-
gesting possible adverse events at every study visit, including early study re-
view visits for participants in the intervention group, and sought relevant da-
ta in case note reviews. Due to the pragmatic trial design, no equivalent early
study visits were done for participants in the control group; thus we anticipat-
Grant 2020 
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Low risk Quote: "Vital status at 6 months was determined for 1487 (98.7%) of 1507 par-




Low risk Comment: the authors prespecified primary and secondary outcomes for
analysis, which they reported.
Other bias Low risk Although there were some differences between the intervention and stan-
dard-of-care groups, notably the presence of tuberculosis symptoms, prior re-
ceipt of isoniazid preventive therapy, and receipt of tuberculosis tests in the







Participants 2574 HIV-positive adults, inpatients (unselected)
Interventions Urine LAM + urine Xpert + sputum Xpert versus standard of care (which included sputum Xpert)
Outcomes Mortality
Notes Mortality assessed at 56 days.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a randomisation list of unique patient identifiers was generated by the
study statistician using a computer-generated random block size."
Allocation concealment
(selection bias)
Low risk Quote: "On enrolment, study nurses or clinicians took a consecutive sealed
opaque envelope containing the unique patient identifier but not the study
group, to which they remained masked. A paired set of sealed envelopes were
kept in a locked cabinet in the study laboratory, labelled with the unique pa-
tient identifier and containing the study group allocation. These were opened






Low risk Quote: "Investigators, all study staQ (other than the laboratory technician and
statistician), hospital attending clinical teams, and patients were masked to
the study group allocation."
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "tuberculosis screening results were reported to the attending clini-
cal team as positive, negative, or not done to maintain masking, with neither
study group nor individual test results communicated to attending clinical or
study teams."
Gupta-Wright 2018 
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Low risk Comment: the authors prespecified primary and secondary outcomes for
analysis, which they reported.
Other bias Unclear risk Comment: did not include a culture reference standard, used laborato-
ry-based rather than bedside LAM, consent requirements may have biased






Participants 2528 HIV-positive adults, inpatients (symptoms)
Interventions Urine LAM plus TB diagnostic tests: smear, Xpert, and culture versus standard TB diagnostic tests:
smear, Xpert, and culture
Outcomes Mortality
Notes Mortality assessed at 8 weeks.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "We randomly assigned eligible patients..using computer generated al-
location lists."




Low risk Quote: "Once an eligible patient was identified, the research nurse at each site
(who did not have access to these lists) either contacted a centrally located da-
ta manager by telephone to obtain assignment or used a text-message system,





Unclear risk Quote: "Neither patients nor research nurses were masked to either allocation
or test results."
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Quote: "8-week outcome data were available for 2411 (95%) of 2528 patients in
the modified Intention-to-treat analysis."
Peter 2016 
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Selective reporting (re-
porting bias)
Low risk Comment: the authors prespecified primary and secondary outcomes for
analysis, which they reported.
Other bias Unclear risk Heterogeneous mortality effect noted across the four countries in which the
study was conducted. Variable use of tuberculosis diagnostics and treatment
across the study sites. Variable illness severity across sites. Consent require-
ments may have biased study towards a less sick population.
Peter 2016  (Continued)
BMI: body mass index
LAM: lipoarabinomannan
RCT: randomized controlled trial
TB: tuberculosis
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Blanc 2020 Standard-of-care arm utilized a diagnostic strategy that did not include any of the tuberculosis
tests described in our protocol as criteria for inclusion, and study was not used to guide clinical
decision-making, precluding comparison of the impact of LF-LAM compared to other diagnostic
strategies.
Cummings 2019 Not an RCT
Gupta-Wright 2019 Not an RCT
Huerga 2019 Not an RCT
Kubiak 2018 Not an RCT
Mathabire Rucker 2019 Not an RCT
Mthiyane 2019 Not an RCT
Naidoo 2019 Not an RCT
LF-LAM: lateral flow urine lipoarabinomannan assay
RCT: randomized controlled trial
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Meta-analyses comparing mortality for LAM versus standard of care
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1 Mortality at 8 weeks, inpatient settings 2 5102 Risk Ratio (M-H, Fixed,
95% CI)
0.85 [0.76, 0.94]
1.2 Sensitivity analysis - 25% mortality in
missing participants (LAM) and 0% in missing
participants (standard of care)
2 5233 Risk Ratio (M-H, Fixed,
95% CI)
0.87 [0.78, 0.97]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.3 Sensitivity analysis - 0% mortality in miss-
ing participants (LAM) and 25% in missing
participants (standard of care)
2 5233 Risk Ratio (M-H, Fixed,
95% CI)
0.82 [0.74, 0.91]





Analysis 1.1.   Comparison 1: Meta-analyses comparing mortality for LAM






Heterogeneity: Chi² = 0.12, df = 1 (P = 0.73); I² = 0%
Test for overall effect: Z = 3.07 (P = 0.002)
























M-H, Fixed, 95% CI
0.86 [0.74 , 1.01]
0.83 [0.72 , 0.96]
0.85 [0.76 , 0.94]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours SoC
 
 
Analysis 1.2.   Comparison 1: Meta-analyses comparing mortality for LAM versus standard of care, Outcome 2:






Heterogeneity: Chi² = 0.02, df = 1 (P = 0.88); I² = 0%
Test for overall effect: Z = 2.57 (P = 0.01)
























M-H, Fixed, 95% CI
0.86 [0.74 , 1.01]
0.88 [0.76 , 1.01]
0.87 [0.78 , 0.97]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours SoC
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Analysis 1.3.   Comparison 1: Meta-analyses comparing mortality for LAM versus standard of care, Outcome 3:






Heterogeneity: Chi² = 0.82, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 3.69 (P = 0.0002)
























M-H, Fixed, 95% CI
0.86 [0.74 , 1.01]
0.78 [0.68 , 0.90]
0.82 [0.74 , 0.91]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours SoC
 
 
Analysis 1.4.   Comparison 1: Meta-analyses comparing mortality for LAM






Test for overall effect: Z = 1.07 (P = 0.28)



















M-H, Fixed, 95% CI
0.89 [0.71 , 1.11]
0.89 [0.71 , 1.11]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours SoC
 
 
Comparison 2.   Meta-analyses comparing mortality for LAM versus standard of care, stratified by CD4 strata
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.1 Mortality at 8 weeks, inpatients -
stratified by CD4 ≤ 100 versus > 100
cells/µL
2 4883 Risk Ratio (M-H, Random,
95% CI)
0.85 [0.73, 0.99]
2.1.1 CD4 ≤ 100 cells/µL 2 2016 Risk Ratio (M-H, Random,
95% CI)
0.88 [0.77, 1.01]
2.1.2 CD4 > 100 cells/µL 2 2867 Risk Ratio (M-H, Random,
95% CI)
0.80 [0.55, 1.17]
2.2 Mortality at 8 weeks, inpatients -
stratified by CD4 ≤ 200 versus > 200
cells/µL
2 4903 Risk Ratio (M-H, Random,
95% CI)
0.85 [0.75, 0.98]
2.2.1 CD4 ≤ 200 cells/µL 2 2886 Risk Ratio (M-H, Random,
95% CI)
0.87 [0.77, 0.98]
2.2.2 CD4 > 200 cells/µL 2 2017 Risk Ratio (M-H, Random,
95% CI)
0.77 [0.48, 1.23]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.3 Mortality at 6 months, outpatients
- stratified by CD4 count < 50 cells/µL
versus ≥ 50 cells/µL
1 1402 Risk Ratio (M-H, Fixed, 95%
CI)
0.89 [0.73, 1.09]
2.3.1 CD4 < 50 cells/µL 1 460 Risk Ratio (M-H, Fixed, 95%
CI)
1.01 [0.78, 1.31]





Analysis 2.1.   Comparison 2: Meta-analyses comparing mortality for LAM versus standard of care, stratified
by CD4 strata, Outcome 1: Mortality at 8 weeks, inpatients - stratified by CD4 ≤ 100 versus > 100 cells/µL
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 1.03, df = 1 (P = 0.31); I² = 3%
Test for overall effect: Z = 1.85 (P = 0.06)





Heterogeneity: Tau² = 0.06; Chi² = 4.35, df = 1 (P = 0.04); I² = 77%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.01; Chi² = 5.66, df = 3 (P = 0.13); I² = 47%
Test for overall effect: Z = 2.15 (P = 0.03)












































M-H, Random, 95% CI
0.81 [0.66 , 1.00]
0.93 [0.78 , 1.11]
0.88 [0.77 , 1.01]
0.96 [0.77 , 1.21]
0.65 [0.49 , 0.87]
0.80 [0.55 , 1.17]
0.85 [0.73 , 0.99]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours LAM Favours SoC
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Analysis 2.2.   Comparison 2: Meta-analyses comparing mortality for LAM versus standard of care, stratified
by CD4 strata, Outcome 2: Mortality at 8 weeks, inpatients - stratified by CD4 ≤ 200 versus > 200 cells/µL
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 2.21 (P = 0.03)





Heterogeneity: Tau² = 0.08; Chi² = 3.79, df = 1 (P = 0.05); I² = 74%
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.01; Chi² = 4.21, df = 3 (P = 0.24); I² = 29%
Test for overall effect: Z = 2.33 (P = 0.02)












































M-H, Random, 95% CI
0.85 [0.71 , 1.02]
0.89 [0.76 , 1.05]
0.87 [0.77 , 0.98]
0.96 [0.73 , 1.28]
0.60 [0.40 , 0.88]
0.77 [0.48 , 1.23]
0.85 [0.75 , 0.98]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours LAM Favours SoC
 
 
Analysis 2.3.   Comparison 2: Meta-analyses comparing mortality for LAM versus standard of care, stratified by CD4
strata, Outcome 3: Mortality at 6 months, outpatients - stratified by CD4 count < 50 cells/µL versus ≥ 50 cells/µL
Study or Subgroup





Test for overall effect: Z = 0.10 (P = 0.92)





Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 1.83, df = 1 (P = 0.18); I² = 45%
Test for overall effect: Z = 1.11 (P = 0.26)


































M-H, Fixed, 95% CI
1.01 [0.78 , 1.31]
1.01 [0.78 , 1.31]
0.76 [0.55 , 1.05]
0.76 [0.55 , 1.05]
0.89 [0.73 , 1.09]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours [intervention] Favours [standard of care]
 
 
Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV (Review)










Cochrane Database of Systematic Reviews
Comparison 3.   Meta-analyses comparing proportion of participants treated for tuberculosis for LAM versus
standard of care
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
3.1 Proportion of participants treated for tu-
berculosis, inpatient settings
2 5102 Risk Ratio (M-H, Ran-
dom, 95% CI)
1.26 [0.94, 1.69]
3.2 Proportion of participants treated for tu-
berculosis, outpatient settings





Analysis 3.1.   Comparison 3: Meta-analyses comparing proportion of participants treated for tuberculosis for






Heterogeneity: Tau² = 0.04; Chi² = 9.88, df = 1 (P = 0.002); I² = 90%
Test for overall effect: Z = 1.52 (P = 0.13)
























M-H, Random, 95% CI
1.47 [1.24 , 1.75]
1.10 [1.01 , 1.19]
1.26 [0.94 , 1.69]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours SoC
 
 
Analysis 3.2.   Comparison 3: Meta-analyses comparing proportion of participants treated for tuberculosis for






Test for overall effect: Z = 22.69 (P < 0.00001)



















M-H, Random, 95% CI
5.44 [4.70 , 6.29]
5.44 [4.70 , 6.29]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LAM Favours SoC
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A D D I T I O N A L   T A B L E S
Study Population Countries Design Intervention Who performed LF-

































Urine LAM (LF-LAM) +














were reported to the at-
tending clinical team as
positive, negative, or not
































































by the study nurse at the
bedside.
Results were verbally
reported to the attend-
ing clinician as LAM is
positive (with grade) or
negative, and if positive,
that TB treatment was
indicated.
84 cells/μL 50 18.8 Primary out-
come:





















































































































































































































































combined in an al-
gorithm and inter-
preted as high, medi-
um, or low probabil-
ity of TB, which was
used to guide treat-
ment decision-mak-
ing versus SoC which
did not specify the
testing approach but
did not include urine
LAM
Study nurses performed
LF-LAM testing in the in-
tervention clinics and
interpreted the results
in conjunction with the
other clinical assess-
ment findings to deter-
mine the probability of
TB, and issued treat-
ment based on a study
algorithm stratified by
the probability of TB.
72 cells/μL NR 21.4 Primary out-
come:








Table 1.   Characteristics of studies that evaluated a diagnostic intervention that included LF-LAM in adults living with HIV  (Continued)
Abbreviations: ART: antiretroviral treatment, BMI: body mass index, LF-LAM: lateral flow urine lipoarabinomannan assay, NR: not reported, RCT: randomized controlled trial, SoC:
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CD4 strata Studies Participants Pooled risk ratios (95% CI)
≤ 100 cells/µL 2 2016 0.88 (0.77 to 1.01)
> 100 cells/µL 2 2867 0.80 (0.55 to 1.17)
≤ 200 cells/µL 2 2886 0.87 (0.77 to 0.98)
> 200 cells/µL 2 2017 0.77 (0.48 to 1.23)
Table 2.   Summary of pooled meta-analysis data evaluating the e<ect of a diagnostic intervention that included LF-
LAM on mortality in inpatient settings, stratified by CD4 count 
LF-LAM: lateral flow urine lipoarabinomannan assay; CI: confidence interval
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
MEDLINE (PubMed) search history
 
   
#9 Search (#3) AND (#7) AND #8)
#8 Search test OR assay OR antigen OR Ag OR lateral flow assay*OR urine antigen OR point of care
Field: Title/Abstract
#7 Search (#4) OR #5) OR #6
#6 Search LAM; Field: Title/Abstract
#5 Search "lipoarabinomannan" [Supplementary Concept]
#4 Search lipoarabinomannan ; Field: Title/Abstract
#3 Search (#1) OR #2)
#2 Search tuberculosis Or TB Field: Title/Abstract
#1 Search ("Tuberculosis"[Mesh]) OR "Mycobacterium tuberculosis"[Mesh]
 
 
Embase 1947-Present, updated daily
Search strategy:
--------------------------------------------------------------------------------
1 tuberculosis.mp. or tuberculosis/ or Mycobacterium tuberculosis/
2 lipoarabinomannan.mp. or lipoarabinomannan/
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3 LAM.mp.
4 2 or 3
5 1 and 4
6 (test or assay or antigen or Ag or lateral flow assay* or urine antigen or point of care).mp.
7 4 and 6
Cochrane Central Register of Controlled Trials, issue 3 of 12, March 2021
#1 tuberculosis:ti,ab,kw (Word variations have been searched)
#2 TB:ti, ab, kw
#3 MeSH descriptor: [Mycobacterium tuberculosis] explode all trees
#4 MeSH descriptor: [Tuberculosis] explode all trees





Search on:         tuberculosis or TB [Words] and lipoarabinomannan or LAM [Words]
 
Science Citation Index Expanded (SCI-EXPANDED), Conference Proceedings Citation Index- Science (CPCI-S),  and BIOSIS Pre-
views (all from Web of Science)
 
 
TOPIC:   (tuberculosis or TB)   AND  TOPIC:   (lipoarabinomannan or LAM)   AND  TITLE:   (test OR assay OR antigen OR Ag OR lateral flow
assay*OR urine antigen OR point of care)
Scopus
( ( TITLE-ABS-KEY ( tuberculosis  OR  tb ) )  AND  ( lam  OR  lipoarabinomannan ) )  AND  ( TITLE ( test  OR  assay  OR  antigen ) )
Proquest Dissertations & Theses
ab(tuberculosis) AND (lam OR lipoarabinomannan) AND ab((test OR assay OR antigen OR Ag OR lateral flow assay*OR urine antigen OR
point of care))
ClinicalTrials.gov
LAM | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Tuberculosis
Also searched for Lipoarabinomannan
WHO ICTRP: LAM or Lipoarabinomannan and tuberculosis
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We revised the  review objective from the protocol (Steingart 2019), such that it is stratified by clinical setting (inpatient versus
outpatient).  Primary stratification by clinical setting is consistent with the  clinical pathway suggested by the current World Health
Organization guidelines (WHO Consolidated Guidelines (Module 3) 2020), since a priori there is likely to be clinical heterogeneity with
respect to inpatient and outpatient participant groups. We were only able to perform meta-analyses for one of our prespecified secondary
outcomes (proportion of participants started on tuberculosis treatment), since data on the other outcomes were either not reported or
only reported in one of the three included studies.
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